For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Regeneron Pharmaceuticals, Inc. (REGN) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Low · Gem Score -25 (−100…+100 Quality+Value blend) · Quality 35 · Value -65 · Sentiment -13 (timing only, not weighted) · Composite fair value $791.80 vs $808.05 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Regeneron Pharmaceuticals, Inc.
REGN NASDAQRegeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio includes treatments such as Eylea and Eylea HD for retinal and eye disorders, Dupixent for inflammatory and allergic conditions, Praluent for cholesterol management, Libtayo in oncology, and Kevzara for rheumatoid arthritis. Regeneron also works on antibody-based medicines and collaborates with partners on advanced research programs, supporting a broad pipeline of therapies. The company serves patients, healthcare providers, and medical systems through prescription medicines used in specialist and hospital care settings. Headquartered in Tarrytown, New York, Regeneron plays a significant role in the biotechnology market by combining drug development, manufacturing, and commercialization across multiple therapeutic areas.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 41.48
Total Equity: $31.26B
Shares: 108,600,000
Total Debt: $1.99B
Cash: $3.12B
EBITDA: $4.12B
Total Debt: $1.99B
Cash: $3.12B
Revenue: $14.34B
Revenue: $14.34B
Revenue: $14.34B
Total Equity: $31.26B
Tax Rate: 13.9%
Equity: $31.26B
Total Debt: $1.99B
Cash: $3.12B
Current Liabilities: $4.37B
Long-Term Debt: $1.99B
Total Debt: $1.99B
Total Equity: $31.26B
Shares: 108,600,000
Shares: 108,600,000
CapEx: -$898.40M
Shares: 108,600,000
Stock Price: $808.05
Net Income: $4.50B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 6, 2026 1:09pm (62d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | — | — | — | — | — |
| Operating Income | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B |
| Net Income | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| EBITDA | $9.2B | $5.1B | $4.5B | $4.5B | $4.1B |
| EPS | $76.40 | $40.51 | $37.05 | $40.90 | $43.07 |
| EPS (Diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
Balance Sheet (Annual)
Last updated: Aug 6, 2026 1:09pm (62d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.9B | $3.1B | $2.7B | $2.5B | $3.1B |
| Total Current Assets | $14.0B | $15.9B | $19.5B | $18.7B | $18.0B |
| Total Assets | $25.4B | $29.2B | $33.1B | $37.8B | $40.6B |
| Current Liabilities | $3.9B | $3.1B | $3.4B | $3.9B | $4.4B |
| Long-Term Debt | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B |
| Total Liabilities | $6.7B | $6.6B | $7.1B | $8.4B | $9.3B |
| Total Equity | $18.8B | $22.7B | $26.0B | $29.4B | $31.3B |
| Retained Earnings | $19.0B | $23.3B | $27.3B | $31.7B | $35.8B |
Cash Flow (Annual)
Last updated: Aug 6, 2026 1:09pm (62d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.1B | $5.0B | $4.6B | $4.4B | $5.0B |
| Capital Expenditure | -$551.9M | -$590.1M | -$718.6M | -$755.9M | -$898.4M |
| Free Cash Flow | $6.5B | $4.4B | $3.9B | $3.7B | $4.1B |
| Acquisitions (net) | $0 | -$230.3M | -$54.9M | -$16.5M | -$3.3M |
| Net Debt Issued / (Repaid) | $0 | $0 | — | — | — |
| Dividends Paid | — | — | $0 | $0 | -$370.3M |
| Stock Buybacks | -$1.6B | -$2.1B | -$2.2B | -$2.6B | -$3.4B |
| Net Change in Cash | $690.8M | $221.3M | -$381.6M | -$248.8M | $634.7M |
Growth Trends (YoY %)
Last updated: Aug 6, 2026 1:09pm (62d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -24.3% | +7.8% | +8.3% | +1.0% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -47.0% | -14.6% | -1.4% | -10.3% |
| Net Income Growth | -46.3% | -8.9% | +11.6% | +2.1% |
| EBITDA Growth | -45.0% | -12.1% | +0.1% | -7.9% |
Dividend History (Last 20)
Last updated: Aug 10, 2026 12:02am (59d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-18 | $0.94 | — | — | — |
| 2026-05-20 | $0.94 | — | — | — |
| 2026-02-20 | $0.94 | — | — | — |
| 2025-11-20 | $0.88 | — | — | — |
| 2025-08-18 | $0.88 | — | — | — |
| 2025-05-20 | $0.88 | — | — | — |
| 2025-02-20 | $0.88 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-07 02:03A +1σ run of quarters pays +5%; a −1σ run costs 51%. Ratio 0.1:1 (μ 8.6%, σ 9.4% , 16 pairs).
Older method (repeat-worst-quarter): 0.7 : 1
| Case | Growth | Margin | Fair value | vs price ($808.05) |
|---|---|---|---|---|
| Bull — recovery | +21% | 32.0% | $1,056.46 | +31% |
| Base — stabilizes | +14% | 27.9% | $750.51 | -7% |
| Bear — keeps slipping | +7% | 23.7% | $519.77 | -36% |
| Stress — last quarter repeats | +1% | 24.0% | $431.91 | -47% |
| Upside — a +1σ run of quarters (v2) | +18% | 27.8% | $849.18 | +5% |
| Stress — a −1σ run of quarters (v2) | -1% | 23.1% | $392.92 | -51% |
Narrative Economics
market-narrative step).
Claude Reading
The quarterly trajectory here is more interesting than the "steady compounder" framing suggests. Revenue jumped from $3.03B in Q1'25 to $3.61B in Q1'26 (+19% YoY) and $3.68B to $4.29B in Q2 (+16.5% YoY) — that's a genuine acceleration, not the 1% "recent_revenue_yoy" the momentum module reports (which appears to be comparing stale annual figures). Two quarters of double-digit top-line growth after years of ~$3.7B ceilings deserve more weight than the models give them. Yet net income tells a different story: Q1'26 margins collapsed to 20.2% from 26.7% a year prior, and Q2'26 at 30.2% still trails Q2'25's 37.9%. So the acceleration is being bought with margin — likely Libtayo/Dupixent commercial spend and pipeline investment. That's the crux the synthesis glosses over.
The synthesis DCF fair value of $686 assumes ~4-5% revenue CAGR forward, which is what the 5-year lookback shows — but that lookback is contaminated by the 2021 COVID antibody windfall ($16.07B revenue collapsing to $12.17B in 2022). Strip that out and the underlying business has grown from $12.17B (2022) to a run-rate of ~$16B+ implied by H1'26 annualized ($15.8B in just two quarters × 2 = ~$15.8B, but H2 is typically stronger). The 4.6% revenue CAGR is arithmetically correct but economically misleading. If Eylea biosimilar erosion is priced in AND Dupixent + pipeline are delivering the H1'26 print, the composite fair value is too pessimistic. Conversely, if Q1'26's 20% margin is the new normal rather than a blip, then $686 might be generous — $4.5B net income × 19x = $85B market cap, roughly where it trades.
The contrarian case the models underplay: this is a fortress balance sheet ($3.12B cash, $1.99B debt, $31.3B equity, 4.1x current ratio) generating $4.08B FCF at a 6.1x P/S and 19x P/E — cheap for biotech with visible growth reacceleration. ROE of 14.4% and ROIC of 10.2% aren't spectacular but the company is under-levered; a buyback-financed recap could juice returns materially. The insider "S-Sale" of 200 shares is noise, not signal. The market-forces "neutral with Eylea overhang" read is the consensus bear case that's been dogging REGN since 2023 — and yet the last two quarterly revenue prints suggest the transition may already be inflecting. The narrative layer's "+$120 premium for pipeline" framing has it backwards: the premium may actually reflect the market catching on to the H1'26 revenue acceleration that hasn't yet flowed to full-year consensus.
Where I break with the synthesis: I don't think $808 is 15% overvalued. The composite is anchored to trailing 5-year averages that include the COVID distortion and pre-inflection Dupixent economics. If Q3-Q4 2026 confirm the H1 growth rate (~15% YoY on a $16-17B run-rate) with margins normalizing back to 30%+, forward earnings power is $5.5-6B, putting fair P/E-based value at $110-120B market cap or $1,050-1,150/share. If instead Q1'26's margin compression persists and revenue growth was a one-time inventory or launch dynamic, then $686 is right. The data is genuinely thin on which regime we're in — two quarters isn't a trend, and the models are correct that catalysts (GLP-1 readouts, Eylea HD uptake data) will decide it. But labeling this "fully priced" with a -15% gap ignores that the recent quarterly data is running hot relative to the DCF assumptions. Partial dissent: I'd call it fairly valued to modestly undervalued with meaningful upside optionality, not overpriced. Starter position defensible; wait for Q3 print to confirm before sizing up.
GPT Reading
Regeneron looks less like a growth biotech than a cash-rich franchise defending its earnings base, and at $808 the market is paying a premium for that defense to work smoothly. The first thing that stands out is how little the annual top line has actually grown relative to the valuation: revenue was $16.07B in 2021, fell hard to $12.17B in 2022 as pandemic-era business rolled off, and has only rebuilt to $14.34B by 2025. Even ignoring the COVID distortion, 2024 to 2025 revenue rose just 1% from $14.20B to $14.34B, while operating income fell from $3.99B to $3.58B. That is not the profile that normally deserves nearly 20x earnings and 5.7x revenue unless investors are underwriting a clean reacceleration. The quarterly run-rate is somewhat better, with 2026 Q2 revenue of $4.29B up sharply from $3.68B in 2025 Q2 and net income of $1.30B versus $1.39B a year earlier, but that still tells a mixed story: sales are moving, profitability is not compounding cleanly.
The numbers suggest a transition that is real but not yet comfortably won. Over the last eight quarters, revenue has climbed from $3.03B in 2025 Q1 to $4.29B in 2026 Q2, which is encouraging, but net margin has swung from 26.7% to 37.9% to 38.9% and then back down to 21.7%, 20.2%, and 30.2%. A company with Regeneron’s scientific reputation and balance sheet should be able to convert growth into steadier operating leverage than this. Instead, what I see is a business offsetting pressure in mature assets with newer growth drivers, but not yet doing so with enough consistency to justify a “steady compounder” label. Cash generation remains solid — $4.98B in operating cash flow and $4.08B in free cash flow in 2025 — yet even that only modestly covers an $83B market cap at about a 4.9% FCF yield. For a company with revenue CAGR of just 4.6% and earnings CAGR of 6.7%, that is acceptable, not obviously cheap.
The balance sheet is the main reason this is not a bearish call. Regeneron has $3.12B of cash against just $1.99B of debt, a current ratio above 4, and book equity of $31.26B, so there is no financial stress angle here at all. Return metrics are good but not elite for the multiple being paid: ROE of 14.4%, ROIC of 10.2%, ROA of 11.1%. Those are strong large-cap healthcare numbers, but they do not scream hidden compounding machine at 2.8x book and nearly 20x EBITDA-equivalent valuation. Put differently, the company is excellent, but the stock already knows it. I come out closer to “good business, full price” than to either deep value or obvious short.
The strongest case against this view is the obvious one: the quarterly inflection may be more important than the annual stagnation. If the business has truly turned the corner, then looking at 2024 and 2025 annuals understates current earnings power. 2026 Q2 revenue of $4.29B annualizes to more than $17B, well above the prior peak, and net income of $1.30B in the quarter implies an earnings run-rate materially above 2025. On that basis, the trailing P/E of 19.5x may be overstating the real forward multiple, perhaps by a lot. The market may also be right to pay above classic pharma multiples for a company with genuine innovation capacity, low leverage, and multiple shots on goal beyond current franchises. If 2026 is the year the mix shift stops being a headwind and starts being growth, then $808 may prove entirely reasonable.
What would change my mind is not another clinical narrative but a cleaner financial pattern. If the next two quarters sustain revenue above $4.0B with net margins back into the mid-30s, and if annual operating income starts growing again rather than shrinking as it did in 2025, then I would accept that the business has earned a higher multiple and likely move fair value toward the current price or above. Conversely, if revenue slips back toward the high-$3B range or margins revisit the low-20s despite higher sales, that would confirm the market is paying for a transition that remains incomplete and push my fair value into the high-$600s to low-$700s.
Grok Reading
The numbers describe a high-quality cash machine that has stopped growing in any meaningful way. Regeneron printed $14.34B in 2025 revenue after $14.20B the year before—barely 1% growth—and the five-year revenue CAGR sits at a pedestrian 4.6% once the 2021 COVID antibody spike is stripped out. Operating income has compressed from $8.95B in 2021 to $3.58B in 2025; free cash flow of $4.08B remains excellent and the balance sheet is fortress-like ($3.12B cash, $1.99B debt, D/E 0.06), but the market is paying 19.5× earnings and 5.7× EV/revenue for mid-single-digit earnings growth and a company whose flagship retinal franchise faces known biosimilar pressure. The recent $4.29B June-quarter print is the best sequential step-up in the series and lifts TTM revenue toward ~$15.5B, yet net margins still swing violently between 20% and 39% quarter to quarter, underscoring residual product-mix and collaboration-timing noise rather than a clean re-acceleration. At $808 the stock embeds a roughly 15–18% premium to the ~$686 fundamental anchor the models derive from Eylea-plus-Dupixent cash flows; that premium is pure pipeline and platform optionality.
What stands out is the mismatch between the “mature earner” cash-flow profile and the multiple still being paid. ROIC of 10.2% and ROE of 14.4% are respectable but not scarce enough to justify nearly 20× earnings when revenue is essentially flat and operating leverage has been running in reverse for four years. The Q2 revenue bounce is real, yet it arrives against a backdrop of only 2.1% earnings growth year-over-year and an FCF CAGR of just 2.6%. Insiders are not buying; the single recent sale is noise. Macro headwinds and a sector that already prices antibody platforms richly leave little margin of safety if Dupixent’s next leg of COPD and pediatric expansion disappoints or if Eylea HD fails to fully offset the original molecule’s erosion.
The strongest counter-argument is that the market is rationally capitalizing a still-expanding Dupixent franchise plus a credible late-stage pipeline (obesity collaboration, oncology) that is not yet in the numbers. A smart opponent would note the pristine FCF conversion, the 4.1 current ratio, net-margin durability above 30% on an annual basis, and the fact that 19.5× is actually a discount to high-growth biotech and only a modest premium to big pharma—reasonable if one believes the antibody-discovery engine can keep launching multi-billion-dollar assets. They would also point to the $4.29B quarter as early evidence that the franchise transition is already being navigated successfully. I weigh this less heavily because the same data show operating income still 60% below the 2021 peak, revenue CAGR stuck in the mid-single digits, and the entire $120-per-share premium resting on clinical outcomes that remain binary and several quarters away; until those readouts convert into reported sales, the multiple is paying for hope rather than demonstrated re-acceleration.
I would flip to neutral or constructive on two clean prints of double-digit year-over-year revenue growth that explicitly show Dupixent plus Eylea HD more than offsetting biosimilar losses, or on positive pivotal data from the GLP-1 or oncology programs that visibly de-risk the pipeline contribution inside the next twelve months. A sustained drop below $700 without deterioration in the core P&L would also force a reassessment of the risk/reward.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Regeneron sits on $8.61B of liquid cash against $6.62B net cash, generates $4.08B FCF at a 28% FCF margin, and posts an Altman Z of 7.65 with OCF/NI of 1.06x and negative accruals (-0.3% of assets). Earnings integrity looks clean on the mechanical checks and cash conversion is real. Capital discipline is a genuine strength: diluted share count fell from 115.1M to 108.6M in the latest year (-0.8% CAGR overall, sharper in 2025), and buybacks run 2.87x SBC despite SBC being a non-trivial 6.9% of revenue. The concern is the trajectory of the core P&L. Operating margin has slid every single year from 55.7% (2021) to 38.9% to 30.9% to 28.1% to 24.9%, and revenue has essentially stalled at $14.2B-$14.3B for two years after collapsing from the $16.07B COVID peak. Net income is flat around $4.4B-$4.5B. The margin decay is either R&D reinvestment (which is defensible for a biotech) or a signal of pricing/competitive pressure on Eylea from biosimilars and Vabysmo. Either way, the operating leverage has been running the wrong direction for four consecutive years, which caps how high on the quality frame this can sit despite the fortress balance sheet.
Verify before trusting this (5)
- Eylea revenue trajectory and biosimilar/Vabysmo share loss in the 10-K segment disclosures
- R&D expense line to determine how much of the OpM decline is deliberate pipeline reinvestment vs gross margin pressure
- Dupixent collaboration economics with Sanofi and whether that growth is offsetting Eylea erosion
- Pipeline readouts (Libtayo, factor XI, oncology) that would justify sustained R&D intensity
- Customer/payer concentration and any Medicare Part B pricing exposure
The e2e composite pins fair value at $678 and the signal-adjusted read at $686, implying roughly -15% downside from $808. The DCF ($700) and EPV floor ($450) both sit well below the market price; only the anchored-PE method ($863) supports today's tape, and that method extrapolates a multiple from a period that included the COVID windfall and pre-margin-compression profitability. Given operating margins have fallen from 55.7% to 24.9% over five years and revenue has been flat for two, leaning on historical multiples flatters the deserved value.
Verify before trusting this (5)
- Eylea HD uptake trajectory vs biosimilar timing in next 10-Q
- Dupixent YoY growth deceleration curve and new-indication contribution
- Operating margin stabilization - is 24.9% the trough or a waypoint down
- R&D productivity signals from obesity and oncology readouts
- Any guidance revisions or one-time charges masking core run-rate earnings
REGN sits in a mild risk-on regime (score +47, VIX 15.5), but with a beta of 0.19 the tape hardly moves this name either way. The macro crosswind that matters more here is the 4.65% 10y and stretched market PE - large-cap biotech with steady cash flows is relatively insulated, and if anything a slightly nervous tape favors defensive healthcare compounders over story stocks. Net macro pressure on this specific ticker is close to neutral, leaning very slightly positive. The active narrative is a moderate-intensity, moderate-durability steady-compounder story with a clear overhang: Eylea biosimilar timing and Dupixent deceleration. Nothing in the last 72h escalates or breaks that story - the news flow (dividend confirmed, buybacks, in-line H1 2026) is textbook boring-compounder maintenance, which reinforces the archetype but adds no narrative fuel. Analyst tone is not showing a target-revision wave in either direction. So the pressure is genuinely balanced: no euphoric bid, no active de-rating, just a stock trading on its own cadence while the market's dominant AI/growth narrative flows elsewhere and leaves this name un-loved but un-punished.
Verify before trusting this (5)
- Any Eylea biosimilar approval or launch-timing update from the FDA or competitors
- Dupixent quarterly script trend and any label-expansion readouts
- Pipeline catalyst dates (GLP-1 Roche collaboration data, late-stage oncology readouts) that could reignite the bull narrative
- Analyst target-price revisions clustering in either direction after H1 2026 print
- Rotation into or out of defensive large-cap biotech versus AI/growth
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 11, 2026, REGN was $808.05. We expect it to be $755.00 by Feb 2027, and we consider it great value under $640.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 11, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
trailing_eps
flips down 25%
adjusted_pe
flips down 25%